S
SciClone Pharmaceuticals
A global specialty pharmaceutical company with a product portfolio of therapies for cancer and infectious diseases
About SciClone Pharmaceuticals
SciClone Pharmaceuticals is a biopharmaceutical firm with an integrated platform for developing and commercializing pharmaceutical products. Founded in May 1990 by Thomas E. Moore and Nelson M. Schneider in California, the company initially aimed to acquire and develop pharmaceuticals for global marketing. SciClone's predecessor was listed on NASDAQ in March 1992. In 2017, the company underwent a privatization led by a consortium of Chinese investors, including GL Capital Management, and was subsequently delisted from NASDAQ in October 2017. A significant milestone was its official listing on the Main Board of the Hong Kong Stock Exchange on March 3, 2021, which raised approximately HK$2.2 billion. However, the company was later taken private again by GL Capital, with the privatization completed on July 3, 2024, for approximately US$1.13 billion.
The company's business model centers on the sale of its proprietary product, Zadaxin, alongside a portfolio of in-licensed and promoted products within Mainland China. Revenue is generated through the sale of these pharmaceutical products, distributed to hospitals and pharmacies. SciClone has strategically focused on high-growth therapeutic areas with unmet needs in China, particularly oncology and severe infections. Its proprietary product, Zadaxin (Thymalfasin), is a key revenue driver, used for treating hepatitis B and certain cancers, and has been noted for its role during the SARS and COVID-19 outbreaks. The company has also expanded its portfolio through in-licensing agreements, acquiring commercialization rights for products like Novartis's Zometa and The Medicines Company's Angiomax. A 'Go-To-Patient' (GTP) model has been implemented to extend sales beyond hospitals directly to pharmacies, significantly increasing patient accessibility. This business strategy involves acquiring licenses and participating in various stages of the product development lifecycle.
Under the leadership of President and CEO Hong Zhao, who joined in 2013, SciClone has focused on strategic transformation and operational excellence. Zhao, with over 30 years in the pharmaceutical industry and a background that includes senior roles at Novartis China and Simcere Pharmaceutical Group, has guided the company's shift towards an innovation-driven model. His leadership was instrumental in the 2021 Hong Kong IPO. The company's pipeline includes a range of drug candidates in various clinical stages, from early-stage IND filings to late-stage pivotal trials, addressing conditions such as solid tumors, pneumonia, and various cancers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1990
- Headquarters
- Foster City, United States
- Listing
- IPO 1992
- Employees
- 119
- Open positions
- 1
- Dealroom signal
- 43.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS
- Client focus
- B2C
- Investment activity
- 2 companies, latest Apr 2011
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Mar 2021 | $279M | $1.6B | Undisclosed | — |
| BUYOUT✓Exit | Jun 2017 | $605M | $605M | GL Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SciClone Pharmaceuticals is 2K monthly website visits, up 412.8% over the last three months. SciClone Pharmaceuticals's team grew 33.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NovaMed PharmaceuticalsBaoshan District, ChinaNovaMed Pharmaceuticals is focused on sales and marketing, register, circulation, manufacture, and R&D through virtual intergration
$105Mvaluation
SciClone Pharmaceuticals in the Foster City ecosystem
The SciClone Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- GCGL Capital
Other known investors1 additional known investor
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about SciClone Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SciClone Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










